Due to high levels of tumor‐infiltrating lymphocytes and PD‐L1 expression, TNBC is the breast cancer subtype most amenable to immunotherapy.[50] Indeed, PD‐1 blockers have been approved as first‐line treatment for PD‐L1‐positive metastatic TNBC patients, and new immunotherapeutic strategies are actively being developed.[51, 52, 53, 54] TNBC is a heterogeneous disease with diverse immunogenicity. This evidence concerns the gene CD274 and neoplasm.